These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26031699)

  • 1. Atrial fibrillation: Uninterrupted oral anticoagulation in patients undergoing catheter ablation.
    Mearns BM
    Nat Rev Cardiol; 2015 Jul; 12(7):381. PubMed ID: 26031699
    [No Abstract]   [Full Text] [Related]  

  • 2. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
    Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
    Kazakov AI; Yashin SM; Lyan EV; Ayrapetyan AV
    Kardiologiia; 2015; 55(8):30-4. PubMed ID: 26761969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation.
    Im SI; Jeong DS; Park SJ; Park KM; Huh J; Kim JS; On YK
    Int J Cardiol; 2015; 186():213-5. PubMed ID: 25828118
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin.
    Tao S; Otomo K; Ono Y; Osaka Y; Hirao T; Koura K; Manno T; Ueshima D; Shimizu S; Isobe M; Hirao K
    J Interv Card Electrophysiol; 2017 Mar; 48(2):167-175. PubMed ID: 27943112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
    Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry.
    Di Biase L; Briceno DF; Trivedi C; Mohanty S; Gianni C; Burkhardt JD; Mohanty P; Bai R; Gunda S; Horton R; Bailey S; Sanchez JE; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Reddy YM; Zagrodzky J; Hongo R; Beheiry S; Lakkireddy D; Natale A
    Heart Rhythm; 2016 Jun; 13(6):1197-202. PubMed ID: 26994940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Periprocedural and Early Pericardial Effusions With Tamponade Following Ablation of Atrial Fibrillation With Uninterrupted Factor Xa Inhibitors: A Case Series.
    Gianni C; DI Biase L; Mohanty S; Trivedi C; Bai R; Al-Ahmad A; Burkhardt JD; Gallinghouse GJ; Horton RP; Sanchez JE; Hranitzky PM; Lakkireddy D; Mansour MC; Santangeli P; Zado ES; Marchlinski FE; Beheiry S; Hao SC; Couts L; Gibson D; Natale A
    J Cardiovasc Electrophysiol; 2016 Apr; 27(4):399-403. PubMed ID: 26756289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 14. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
    Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
    Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M
    J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
    Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
    Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
    J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
    Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
    J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locked Away: Percutaneous Closure of a Malignant Left Atrial Appendage to Constrain an Unresolvable Thrombus.
    Dugo D; Bordignon S; Konstantinou A; Perrotta L; Fürnkranz A; Chun JK; Schmidt B
    Circ Arrhythm Electrophysiol; 2016 Aug; 9(8):. PubMed ID: 27489242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.